Siltuximab Shows Promising Efficacy Against CRS and ICANS
Researchers sought to determine whether siltuximab would be safe and effective for treating CRS and ICANS associated with CAR-T therapy.
Researchers sought to determine whether siltuximab would be safe and effective for treating CRS and ICANS associated with CAR-T therapy.
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.
Researchers sought to determine whether CR rates were improved using CAR-T therapy in patients with central nervous system lymphoma.
Researchers sought to determine whether lisocabtagene maraleucel would improve health-related quality of life in patients with relapsed/refractory LBCL.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Researchers sought to determine the unmet need in patients with aggressive B-cell lymphomas whose disease relapses after CAR-T therapy.
Researchers say they have identified 28 signs and symptoms that can facilitate early recognition of toxicity associated with CAR T-cell therapy.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.